What is Scisparc Ltd?
, a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 869.84K.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.